Edition:
United States

Nuvectra Corp (NVTR.OQ)

NVTR.OQ on NASDAQ Stock Exchange Global Market

13.46USD
23 Apr 2018
Change (% chg)

$-0.29 (-2.11%)
Prev Close
$13.75
Open
$13.82
Day's High
$13.82
Day's Low
$13.43
Volume
11,035
Avg. Vol
28,334
52-wk High
$14.55
52-wk Low
$7.34

Latest Key Developments (Source: Significant Developments)

Nuvectra Q4 Loss Per Share $0.80
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - Nuvectra Corp ::NUVECTRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.80.Q4 REVENUE ROSE 188 PERCENT TO $12 MILLION.  Full Article

Nuvectra Says Public Offering Of 2.83 Mln Shares Priced At $8 Per Share
Thursday, 1 Feb 2018 09:00am EST 

Feb 1 (Reuters) - Nuvectra Corp ::NUVECTRA™ ANNOUNCES PRICING OF FOLLOW-ON STOCK OFFERING.SAYS PUBLIC OFFERING OF 2.83 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.  Full Article

Nuvectra Sees Q4 Revenue $11.5 Mln To $12 Mln
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Nuvectra Corp ::NUVECTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2017 REVENUE.SEES Q4 REVENUE $11.5 MILLION TO $12 MILLION.SEES FY 2017 REVENUE $31.5 MILLION TO $32 MILLION.  Full Article

Nuvectra reports Q3 loss per share $1.09
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Nuvectra Corp :Nuvectra reports third quarter 2017 financial results.Q3 loss per share $1.09.Q3 revenue rose 102 percent to $7.6 million.  Full Article

Nuvectra corp files for mixed shelf of upto $100 mln
Thursday, 5 Oct 2017 02:16pm EDT 

Oct 5 (Reuters) - Nuvectra Corp :Nuvectra Corp files for mixed shelf of upto $100 million - sec filing‍​.  Full Article

Nuvectra corp says effective Aug. 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics - SEC filing
Tuesday, 5 Sep 2017 09:47am EDT 

Sept 5 (Reuters) - Nuvectra Corp :Nuvectra Corp - effective august 31, co entered into amended and restated development agreement with Aleva Neurotherapeutics, S.A - SEC filing.Nuvectra corp - agreement amends and restates terms of development agreement between Aleva and Nuvectra, dated January 29, 2016.Nuvectra Corp-Aleva and Nuvectra agree to collaborate on development of deep brain stimulation product that may be used to treat Parkinson's disease.Nuvectra Corp - Aleva will pay nuvectra monthly for all services it provides on a time and material basis, as invoiced by Nuvectra.  Full Article

Nuvectra Q2 loss per share $1.07
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Nuvectra Corp :Nuvectra reports second quarter 2017 financial results.Q2 loss per share $1.07.Q2 revenue rose 183 percent to $7.2 million.  Full Article

Nuvectra unit enters into business property lease agreement
Friday, 30 Jun 2017 04:57pm EDT 

June 30 (Reuters) - Nuvectra Corp ::Nuvectra Corp - effective July 1, 2017, unit entered into a business property lease agreement with BMT Ann Arbor, Llc.  Full Article

Nuvectra enters second amendment to development agreement with Aleva Neurotherapeutics
Wednesday, 21 Jun 2017 05:17pm EDT 

June 21 (Reuters) - Nuvectra Corp -:Nuvectra- effective june 19, co entered second amendment to development agreement with aleva neurotherapeutics, s.a to amend agreement dated jan 29, 2016.Nuvectra-Under terms, aleva, co to modify payment schedule, timing of certain payments, any additional work performed by co to be paid on monthly basis.  Full Article

Nuvectra files regulatory submission with FDA for Algovita MRI-conditional approval
Wednesday, 21 Jun 2017 07:00am EDT 

June 21 (Reuters) - Nuvectra Corp :Nuvectra files regulatory submission with fda for Algovita MRI-conditional approval.Nuvectra -submission, pending regulatory approval from FDA, would position company to achieve MRI-conditional approval at or around year end 2017.  Full Article

BRIEF-Nuvectra Q4 Loss Per Share $0.80

* NUVECTRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS